Stock of the Day

Insmed (INSM)

$73.28

+$0.54 (+0.7%)

Market Cap: $13.37B

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Recent News

• Martina M.D. Flammer Sells 1,686 Shares of Insmed Incorporated (NASDAQ:INSM) Stock (insidertrades.com)
• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (prnewswire.com)